GeoVax's Chief Scientific Officer Interviewed on HealthRadio.net

SMYRNA, Ga., July 22 /PRNewswire-FirstCall/ -- Dr. Harriet L. Robinson, Chief Scientific Officer at GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, discussed the Company's pursuit of a vaccine during a July 20 interview on HealthRadio.net, the leading online talk radio portal devoted to health and medical issues.

Dr. Robinson told her interviewer, Dr. Derrick DeSilva, that medical science is further ahead than many people realize in the quest for a successful HIV/AIDS vaccine. She noted that GeoVax is developing both preventative and therapeutic applications for its vaccine, and expressed her belief that it would serve as a "universal vaccine" for the general population rather than being targeted only to those in high-risk groups.  She reported that the Company is looking forward to having its vaccine progress from a Phase 2 trial, where it stands currently, to a Phase 3 efficacy trial in the next several years.

"The vaccine effort has been moving ahead . . . We still have a way to go, but [creating a successful vaccine] may happen sooner than we think," Dr. Robinson said during the interview. "I think we're knocking on the door [to success], and we've crossed some very important thresholds." Among these is the fact that out of more than 80 vaccine concepts that have entered Phase 1 trials under the auspices of the NIH's HIV Vaccine Trials Network, the GeoVax vaccine is one of just five that have progressed to a Phase 2 trial.

A complete podcast of the interview, titled "Reassessing Where We Stand With an HIV Vaccine," is available at the following link:

http://www.healthradio.net/component/mtree/Health-Radio-Shows/Ask-Dr-2E-DeSilva/Reassessing-Where-We-Stand-With-an-HIV-Vaccine-42579/details

About HealthRadio.net

HealthRadio.net is the world's #1 online Talk Radio portal dedicated to conversational style programming all about Health, Wellness, Fitness, and Medical News & Information. Our staff of professional Talk Radio personalities interview the leading health and medical news makers and top experts in every field of health. We're here to disseminate health and medical information via the spoken word and we feature a 24/7 real-time audio stream including live, interactive programming as well as specific Health Channels that contain thousands of hours of archived Health Talk programs and Podcasts on a myriad of subjects ranging from heart health, cancer, diabetes, women's health and many, many other topics.

Founded by seasoned broadcasting visionary Tim Disa, Sr. - HealthRadio.net partnered with Nature Trade Center in 2009 to form Health Radio Network, LLC. Day to day operations are handled by Operations Director Tim Disa, Jr.  Webmaster, Dave Earley, maintains the Website.  HealthRadio.net has developed strategic affiliations and program production with the American Academy of Pediatrics, American College of Sports Medicine, American College of Emergency Physicians and is currently in discussions with several other prestigious medical organizations. Talk hosts include popular medical/health personalities Dr. Derrick DeSilva, MD; Dr. Michael Roizen, MD; Melanie Cole, MS and other talk show personalities.

About GeoVax Labs, Inc.

GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus – that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, oversee manufacturing and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV immune responses, as well as the vaccines' safety. Successful results from all Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and will ultimately involve 300 participants at sites in the United States and South America. Recently the FDA granted permission to proceed with a Phase 1 therapeutic trial for individuals infected with HIV. Long term, we expect that GeoVax will grant manufacturing and distribution rights in several global markets in return for upfront fees, collaborative development agreements, and royalties on sales and distribution revenues. Internal vaccine manufacturing and distribution will also be considered by GeoVax. For more information, please visit www.geovax.com.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.

SOURCE GeoVax Labs, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED